Queen’s and a nationally recognized academic medical center to provide clinical expertise to enhance GE HealthCare’s forthcoming software solution- New software solution will use AI and predictive ...
Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO II ...
A Breakthrough in Non-Surgical Body Filler for Hips, Breasts, and Buttocks AUSTIN, TX / ACCESS Newswire / October 20, 2025 / The Piazza Center for Plastic Surgery & Advanced Skin Care is among the ...
The "Biopharmaceuticals Contract Manufacturing Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Biopharmaceuticals Contract Manufacturing Market is ...
The "Vaccine Logistics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Vaccine Logistics was valued at US$3.0 Billion in 2024 and is ...
The United States Department of the Navy, Takeda Pharmaceuticals, and Bank of America recognized for aligning their ...
New case study shows how a streamlined digital experience improved lab order adherence, reduced no-shows, and enhanced ...
Rhythio Medical’s soft, conductive hydrogel technology transforms traditional defibrillation into a new class of injectable bioelectronic therapyHOUSTON--(BUSINESS WIRE)--Rhythio Medical, a medical ...
Latest analysis of U.S. real-world evidence demonstrates improved clinical outcomes when cefiderocol is used as earlier ...
Prolong Pharmaceuticals, LLC (the Company), a clinical-stage biopharmaceutical company, today announced that it will present key clinical data from HEMERA-1, its Phase 1/2 clinical trial in Acute ...
Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation ...
New $25 million raise advances multi-node PI3K program; randomized phase 2 trial with Gynecologic Oncology Group Foundation now enrollingAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, a ...